Get the Stockscreener App
7.23
5.39%
0.37
After Hours:
7.26
0.03
+0.41%
Intellia Therapeutics Inc stock is traded at $7.23, with a volume of 2.86M.
It is up +5.39% in the last 24 hours and down -24.53% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$6.86
Open:
$6.85
24h Volume:
2.86M
Relative Volume:
0.88
Market Cap:
$776.38M
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-1.3193
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
+6.79%
1M Performance:
-24.53%
6M Performance:
-65.54%
1Y Performance:
-66.37%
1-Day Range:
$6.80
$7.295
1-Week Range:
$6.65
$7.76
52-Week Range:
$5.90
$28.18
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
7.23 | 776.38M | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
How the (NTLA) price action is used to our Advantage - news.stocktradersdaily.com
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The ... - Bluefield Daily Telegraph
Intellia Therapeutics, Inc. Sued for Securities Law - GlobeNewswire
Final Deadline Today for the Intellia Therapeutics, Inc. Securit - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesNTLA - PR Newswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
Final Deadline Today for the Intellia Therapeutics, Inc. Securities LawsuitContact the DJS Law Group to Discuss Your RightsNTLA - The Malaysian Reserve
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA)April 14, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Business Wire
FINAL REMINDER NTLA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Intellia Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit - markets.businessinsider.com
NTLA Investors are Reminded of the Final Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The Malaysian Reserve
NTLA Investors are Reminded of the Final Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
NTLA Lawsuit Alert! Class Action Lawsuit Against Intellia Therapeutics Inc. - TipRanks
Intellia Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before April 14, 2025 to Discuss Your RightsNTLA - PR Newswire
NTLA Deadline: NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
NTLA Investors Have the Opportunity to Lead the Intellia - GlobeNewswire
NTLA Investors Have the Opportunity to Lead the Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Morningstar
NTLA DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. - Bluefield Daily Telegraph
NTLA DEADLINE ALERT: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
Intellia Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
NTLA Deadline: Rosen Law Firm Urges Intellia Therapeutics, Inc. (NASDAQ: NTLA) Stockholders with Losses in Excess of $50K to Contact the Firm for Information About Their Rights - Eagle-Tribune
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - PR Newswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Intellia Therapeutics, Inc. to Contact the Firm Today! - markets.businessinsider.com
The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNTLA - PR Newswire
NTLA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. - Bluefield Daily Telegraph
Lost Money on Intellia Therapeutics, Inc. (NTLA)? Join - GlobeNewswire
Lost Money on Intellia Therapeutics, Inc. (NTLA)? Join Class Action Suit Seeking Recovery – ... - Bluefield Daily Telegraph
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Morningstar
Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple - Insider Monkey
Vanguard Group Inc. Has $118.82 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - Defense World
Intellia Therapeutics, Inc. (NASDAQ: NTLA) Investor Alert: Deadline in Lawsuit on April 14, 2025 - openPR.com
NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Intellia Therapeutics, Inc. to Contact the Firm Today! - markets.businessinsider.com
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for InvestorsContact Levi & Korsinsky - Morningstar
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - StreetInsider
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion - TradingView
Intellia adopts majority vote for director elections - Investing.com Australia
NTLA IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, - GlobeNewswire
NTLA IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA - TradingView
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia ... - Bluefield Daily Telegraph
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
NTLA Stockholders Have Opportunity to Lead Intellia Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - markets.businessinsider.com
NTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Genome Engineering Market to Witness Remarkable Growth with - openPR.com
Levi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025NTLA - ACCESS Newswire
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of - GlobeNewswire
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit ... - Bluefield Daily Telegraph
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - GlobeNewswire Inc.
NTLA DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, - GlobeNewswire
NTLA DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics - Bluefield Daily Telegraph
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):